Previous 10 | Next 10 |
Syros Pharmaceuticals press release (NASDAQ:SYRS): Q4 GAAP EPS of -$0.38 beats by $0.08. Revenue of $78M (+1268.4% Y/Y) beats by $73.16M. Cash, cash equivalents and marketable securities as of December 31, 2021 were $143.4M. The company believes that its existing cash, cash equivalents and ma...
On Track to Report PK and Safety Data from Ongoing Dose Confirmation Study of SY-2101 in Mid-2022 Expect to Report Clinical Activity from the Safety Lead-In Portions of the Ongoing SELECT-AML-1 Trial of Tamibarotene and the Expansion Cohort of SY-5609 in Pancreatic Cancer in 2...
Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open. The consensus EPS Estimate is -$0.45 (+27.4% Y/Y) and the consensus Revenue Estimate is $4.84M (-15.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upwa...
ANIP, ATNX, BBI, OTCQX:CCHWF, CTRN, DOLE, DTIL, GMDA, KMDA, KNDI, KPLT, NRP, OTCPK:RWEOY, SYRS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial r...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking...
The clinical-stage biotech, Syndax Pharmaceuticals (NASDAQ:SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer, effective immediately. She will replace Michael Meyers, who will remain with the company until June before takin...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual inv...
Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...
The U.S. Food and Drug Administration granted orphan drug designation to Syros Pharmaceuticals' (NASDAQ:SYRS) tamibarotene to treat myelodysplastic syndrome (MDS). Tamibarotene is currently being evaluated in combination with azacitidine in a phase 3 trial, dubbed SELECT-MDS-1, to treat&...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...